- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| 24.04. | Cleanaway rejects suggestion of Seven takeover after shares jump 15% | ||
| 24.04. | Market Open: US tech giants drive rally | ||
| 23.04. | Market Close: ASX drives uphill on continued recovery | ||
| 23.04. | Fe grades above 71% make Cyclone Metals bullish about Iron Bear pilot plant | ||
| 23.04. | Market Update: ASX edges up with a healthier disposition | ||
| 23.04. | Emyria locks in $2.3M to progress MDMA research - with Chair adding $0.3M | ||
| 23.04. | Great Western targets DeGrussa twin through upcoming drilling work | ||
| 23.04. | PharmAust CEO sayanora triggers stock plunge | ||
| 23.04. | AML3D secures Australian defence government contract | ||
| 23.04. | Tamboran steps on the gas to supply the Top End | ||
| 23.04. | Purifloh makes progress on destroying PFAS 'forever chemicals' | ||
| 23.04. | Turaco impressed by gold extraction near 90% from Cote d'Ivoire play | ||
| 23.04. | Fieldwork across Ti-Tree yields regal copper and silver grades for Augustus | ||
| 23.04. | Market Open: ASX200 to keep climbing, as Westpac flags $164m profit downgrade | ||
| 23.04. | Silver Lake going for gold - Wealth Within Hot Stock pick | ||
| 22.04. | Market Close: ASX resurfaces with a brighter smile on its dial | ||
| 22.04. | Not potato, but pegmatites offer future prospectivity for European Lithium in Ireland | ||
| 22.04. | Base Resources and Energy Fuels take off together on critical minerals journey | ||
| 22.04. | Helios teams with NASDAQ-listed Norway firm to liquefy flare gas | ||
| 22.04. | Market Update: Green lights up on the bourse but energy flails | ||
| 22.04. | Lightning Minerals strikes deal to expand into Brazil's Lithium Valley | ||
| 22.04. | Great Boulder goes after more shallow gold at Side Well | ||
| 22.04. | Genetic Signatures wins TGA greenlight for flu test device - just before winter | ||
| 22.04. | Australia continues to beef up domestic crit mineral supply chains | ||
| 22.04. | PYC Therapeutics takes Polycystic Kidney Disease drug to human trials |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und
